Investor Presentaiton

sanofi Immune response in line with other mRNA flu vaccine program mRNA flu QIV results Hemagglutination inhibition titers Sanofi 18-64 years Competitor data¹ >18years 32 In both mRNA trials: % Seroconversion GMTR D29/D01 100 80 60 40 20 16 A/H3N2 A/H1N1 B/YAM B/VIC 0 A/H3N2 A/H1N1 B/YAM B/VIC SP0273 mRNA Flu QIV Fluzone SD 49 Vaccines Investor Event % Seroconversion 1- H1N1 H3N2 135 90- 80- 70- 60- 50- 40- 30- 20- 10- 0. 5 Afluria- 25 50 B/Yamagata B/Victoria T Afluria- H 1. Moderna Third Annual Vaccines Day March 24th, 2022. Phase 2, Age group 18 y and older. DISCLAIMER: data from separate studies should be interpreted with care. H1N1 H3N2 B/Yamagata B/Victoria - A strain results similar to comparator - Low B response is a class effect across mRNA platforms

View entire presentation